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1. Introduction 
1.1 The plasminogen activation system 
Initiation of the plasminogen activation system results in generation of the broad spectrum 
serine protease, plasmin, from the circulating zymogen, plasminogen. Plasminogen is 
activated to plasmin by plasminogen activators (PA’s), either urokinase type-plasminogen 
activator (u-PA) or tissue-type plasminogen activator (t-PA), via specific proteolytic 
cleavage (Castellino & Ploplis, 2005). Plasmin is the major enzyme responsible for 
degradation of fibrin clots (fibrinolysis) to maintain normal blood homeostasis (Bugge et al., 
1995; Ploplis et al., 1995). Dysregulation of the plasminogen activation system can result in 
hemorrhage (excess fibrinolysis) or thrombosis (insufficient fibrinolysis). The plasminogen 
activation system is regulated by direct inhibition of plasmin (by the circulating serpin, ǂ2-
antiplasmin) and by synthesis and secretion of plasminogen activators and the serpin, 
plasminogen activator inhibitor 1 (PAI-1)] (Collen, 1999). In a key regulatory step, 
plasminogen activation is promoted when plasminogen and its activator, t-PA, bind 
concomitantly to lysine residues on the surface of fibrin clots, resulting in a marked 
reduction in the Km for activation of plasminogen compared with the reaction in solution 
(Hoylaerts et al., 1982). 
1.2 Functions of plasminogen receptors 
In the past 25 years an additional mechanism for positive regulation of plasminogen 
activation has been recognized: co-localization of plasminogen and PA’s on cell surfaces 
markedly decreases the Km for plasminogen activation in a mechanism analogous to 
assembly of components of the plasminogen activation system on fibrin (Miles et al., 2005). 
The plasmin produced is retained on the cell surface where it is protected from its inhibitor, 
ǂ2-antiplasmin (Figure 1) (Hall et al., 1991; Plow et al., 1986). Thus, the cell surface becomes 
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armed with the broad spectrum proteolytic activity of plasmin. Cell surface plasmin plays a 
key role in processes in which cells must degrade an extracellular matrix in order to migrate, 
including inflammation (Busuttil et al., 2004; Ploplis et al., 1998; Plow et al., 1999), wound 
healing (Creemers et al., 2000; Romer et al., 1996), metastasis (Palumbo et al., 2003; Ranson et 
al., 1998) and neurite outgrowth (Gutierrez-Fernandez et al., 2009; Jacovina et al., 2001). Cell 
surface plasmin also plays a key role in myogenesis (Lopez-Alemany et al., 2003) and 
prohormone processing (Jiang et al., 2001, 2002). 
 
 
 
Activation of cell-associated plasminogen (Plg) to plasmin (Pm) by cell-associated plasminogen 
activators (PA) is markedly enhanced compared to the reaction in solution. The Pm formed remains on 
the cell surface where it is relatively protected from its inhibitor, ǂ2-antiplasmin (ǂ2-AP). 
Fig. 1. Enhancement of plasminogen activation on the cell surface. 
1.3 Characteristics of plasminogen receptors 
Cellular plasminogen binding sites are very broadly distributed on both prokaryotic and 
eukaryotic cells. Of the many cell types examined to date, only red cells do not exhibit 
detectable plasminogen binding ability (Miles et al., 2005). The interactions of plasminogen 
with cells are of very high capacity, reaching 3 X 107 molecules/cell on lung fibrolasts (Plow 
et al., 1986), for example. Thus, the plasminogen binding capacity of a cell is made up of 
contributions from a set of distinct cell surface proteins. 
An important aspect of the mechanism of promotion of plasminogen activation on cell 
surfaces is that a subset of carboxypeptidase-B-sensitive plasminogen binding proteins is 
responsible for enhancement of plasminogen activation on eukaryotic cells. When cells are 
treated with carboxypeptidase B, the ability to stimulate plasminogen activation is lost 
(Félez et al., 1996). Since carboxypeptidase B removes C-terminal basic residues, these 
results imply that proteins exposing C-terminal basic residues on cell surfaces are 
responsible for stimulation of plasminogen activation (Figure 2,A). Known 
carboxypeptidase-B-sensitive cell surface plasminogen receptors could previously be 
divided into two classes: 1) proteins synthesized with C-terminal lysines and having 
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additional known intracellular functions, including ǂ-enolase (Miles et al., 1991; Redlitz et 
al., 1995), cytokeratin 8 (Hembrough et al., 1995, 1996), S100A10 (Choi et al., 2003; Kassam 
et al., 1998), TIP49a (Hawley et al., 2001) and histone H2B (Herren et al., 2006) and; 2) 
proteins requiring proteolytic processing in order to reveal a C-terminal basic residue 
(lysine), including actin (Dudani & Ganz, 1996; Miles et al., 2006) and annexin 2 (Hajjar et 
al., 1994). However, until recently, no integral membrane plasminogen binding proteins 
synthesized with a C-terminal basic residue had been identified. The existence of a 
plasminogen receptor with the latter characteristics would reveal a novel mechanism for 
stimulation of plasminogen activation because release and rebinding of intracellular 
proteins or proteolytic cleavage of membrane proteins to expose C-terminal basic residues 
would not be required. 
 
 
Plasminogen binding to carboxyl terminal lysines on the cell surface. Panel A) The binding of 
plasminogen to cell surface proteins occurs via receptors exposing carboxyl terminal lysines to the 
extracellular environment. Cell surface proteins with carboxyl terminal lysines that are masked or in 
other inaccessible orientations on the cell surface, or membrane-associated proteins with carboxyl 
terminal lysines that are located on the inner face of the membrane, cannot serve as plasminogen 
receptors. Panel B) CpB treatment of intact cells removes carboxyl terminal lysines from plasminogen 
receptors, and plasminogen binding to the cell surface is reduced. Reprinted with permission from 
(Hawley, Green, and Miles 2000, 84:882-890). 
Fig. 2. Plasminogen binding to carboxyl terminal lysines on the cell surface. 
1.4 Need for a proteomics approach to identify integral membrane plasminogen 
receptor(s) with C-terminal basic residues 
Previous methodologies and characteristics of plasminogen binding proteins may have 
precluded identification of an integral membrane plasminogen binding protein with a C-
terminal basic residue. The identification of plasminogen receptors has relied previously on 
cell surface labeling followed by affinity chromatography on plasminogen-Sepharose 
columns and N-terminal sequencing of fractions eluted from SDS gels. Thus, many 
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intracellular proteins that are also present on the cell surface were readily identified because 
protein fractions that bound to plasminogen-Sepharose included the labeled, surface-
associated protein, as well as nonlabeled intracellular protein. Using these methods, a lower 
abundance integral membrane plasminogen binding protein might not have been 
detectable.  
Previously, we used a proteomics approach to examine monocytoid cell membranes for the 
presence of proteins exposing carboxyl terminal lysines on the extracellular face of the cell 
membrane (Hawley et al., 2000). We compared plasminogen ligand blots of 2-D gels of 
membrane fractions of intact cells treated with carboxypeptidase B with untreated 
membranes (e.g. Figure 2,B). We eluted a prominent carboxypeptidase B-sensitive protein 
from the 2-D gels and obtained two peptide sequences using tandem mass spectrometry. 
These peptide sequences corresponded to TATA-binding protein-interacting protein 
(TIP49a) (Hawley et al., 2001). However, TIP49a is a member of the class of cell surface 
plasminogen receptors synthesized with a C-terminal lysine and also having intracellular 
functions and is not an integral membrane protein.  
The methodology used to identify TIP49a and other plasminogen receptors has required 
elution of candidate proteins from 2-D SDS polyacrylamide gels. However, many membrane 
proteins are not well resolved on SDS polyacrylamide gels. Therefore, we used an isolation 
method that used column chromatography instead of SDS polyacrylamide gel analysis:  We 
took advantage of the exquisite sensitivity of multidimensional protein identification 
technology (MudPIT) to search for integral membrane plasminogen receptor(s) exposing a 
C-terminal basic residue on the cell surface and present on viable cells.  
2. Methods 
2.1 Plasminogen receptor isolation 
Plasminogen receptor isolation was performed as described (Andronicos et al., 2010). 
Briefly, progenitor and M-CSF-differentiated Hoxa9-ER4 cells were separately biotinylated, 
using EZ-Link Amine-PEO3-Biotin. The cells were then subjected to dead cell removal on 
annexin V-coated magnetic microspheres that resulted in a 99% enrichment of viable cells. 
Membrane fractions were prepared from the viable cells by dounce homogenization in the 
presence of Complete Protease Inhibitor Cocktail in Invitrosol, followed by centrifugation 
steps as used in our laboratory (Hawley et al., 2000, 2001) and were applied to a 
plasminogen-Sepharose affinity column as described (Miles et al., 1991). The column was 
washed in phosphate buffered saline containing 1 X Invitrosol until no protein was detected 
at 280 nm followed by elution with the washing buffer containing 0.2 M ε-aminocaproic acid 
(EACA). The eluant from the plasminogen-Sepharose column was incubated with 50l of 
immobilized avidin for 30 minutes at 4°C. The proteins bound to the immobilized avidin 
were resuspended in Invitrosol and heated at 60°C. Then, 80% acetonitrile was added and 
the samples were digested with trypsin. After 24 h, the solvent was evaporated in a 
speedvac, and peptides were dissolved in buffer A (95% H2O, 5% acetonitrile, and 0.1% 
formic acid).  
2.2 Multidimensional chromatography and tandem mass spectrometry 
Multidimensional chromatography and tandem mass spectrometry were performed as 
described (Andronicos et al., 2010). Briefly, the protein digest was subjected to MudPIT 
[reviewed in (Eng et al., 1994)]. Peptide mixtures were resolved by strong cation exchange 
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liquid chromatography upstream of reversed phase liquid chromatography (Larmann, Jr. et 
al., 1993; Link et al., 1999; Opiteck & Jorgenson, 1997; Wolters et al., 2001). Eluting peptides 
were electrosprayed onto an LTQ ion trap mass spectrometer equipped with a nano-LC 
electrospray ionization source. Full MS spectra were recorded over a 400–1600 m/z range, 
followed by three tandem mass (MS/MS) events sequentially generated in a data-dependent 
manner on the first, second, and third most intense ions selected from the full MS spectrum 
(at 35% collision energy). Mass spectrometer scan functions and HPLC solvent gradients 
were controlled by the Xcalibur data system. 
2.3 Database search and interpretation of MS/MS datasets 
Database searching and interpretation of MS/MS Datasets were performed as described 
(Andronicos et al., 2010). Briefly, tandem mass spectra were extracted from raw files, and a 
binary classifier (Bern et al., 2004), previously trained on a manually validated data set, was 
used to remove low quality MS/MS spectra. Remaining spectra were searched against a 
mouse protein database containing 50,370 protein sequences downloaded as FASTA-
formatted sequences from EBI-IPI and 124 common contaminant proteins, for a total of 
66,743 target database sequences (Peng et al., 2003). To calculate confidence levels and false 
positive rates, a decoy database containing the reverse sequences of the 66,743 proteins 
appended to the target database and the SEQUEST algorithm (Yates, III, 1998) were used to 
find the best matching sequences from the combined database.  
SEQUEST searches were done on an Intel Xeon 80-processor cluster running under the 
Linux operating system. The peptide mass search tolerance was set to 3 Da. No differential 
modifications were considered. No enzymatic cleavage conditions were imposed on the 
database search, so the search space included all candidate peptides whose theoretical mass 
fell within the 3 Da mass tolerance window, despite their tryptic status. 
The validity of peptide/spectrum matches was assessed in DTASelect2 (Tabb et al., 2002) 
using SEQUEST-defined parameters, the cross-correlation score (XCorr) and normalized 
difference in cross-correlation scores (DeltaCN). The search results were grouped by charge 
state (+1, +2, and +3) and tryptic status (fully tryptic, half-tryptic, and non-tryptic), resulting 
in 9 distinct sub-groups. In each one of the sub-groups, the distribution of XCorr and 
DeltaCN values for direct and decoy database hits was obtained, and the two subsets were 
separated by quadratic discriminant analysis. Outlier points in the two distributions (for 
example, matches with very low Xcorr but very high DeltaCN) were discarded. Full 
separation of the direct and decoy subsets is not generally possible; therefore, the 
discriminant score was set such that a false positive rate of 5% was determined based on the 
number of accepted decoy database peptides. This procedure was independently performed 
on each data subset, resulting in a false positive rate independent of tryptic status or charge 
state.  
3. Results 
3.1 Isolation of an integral membrane plasminogen receptor exposing a C-terminal 
lysine on the cell surface 
We used specific proteolysis followed by MudPIT to probe the membrane proteome of 
differentiated mouse monocyte progenitor cells (Hoxa9-ER4) for the presence of integral 
membrane plasminogen receptor(s) exposing a C-terminal basic residue on the cell surface, 
as outlined in Figure 3. [The Hoxa9-ER4 cell line was derived from primary murine bone 
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marrow myeloid precursors immortalized with an estrogen regulated conditional 
oncoprotein, HoxA9-ER4 (Wang et al., 2006). The Hoxa9-ER4 line is factor-dependent and 
differentiates to monocytes when estrogen is removed from the medium, thereby 
inactivating the Hoxa9-ER protein. The mature monocytes respond to M-CSF (Odegaard et 
al., 2007)]. First, the  Hoxa9-ER4 monocyte progenitor cells were differentiated with 
macrophage colony stimulating factor (M-CSF), which induces plasminogen receptors on 
these cells (Andronicos et al., 2010). Then intact cells were biotinylated. Because early 
apoptotic and non-viable/necrotic cells exhibit markedly enhanced plasminogen binding 
ability (Mitchell et al., 2006; O'Mullane & Baker, 1998, 1999) we passed the biotinylated cells 
over a dead cell removal column to enrich for live cells. Cells were then lysed and 
membrane fractions prepared and passed over a plasminogen-Sepharose affinity column 
and specifically eluted with ε-aminocaproic acid (EACA), a lysine analog that blocks the 
binding of plasminogen to cells (Miles & Plow, 1985). Biotinylated proteins bound to the 
avidin column and were digested with trypsin while still on the column. The peptide digest 
was then subjected to MudPIT. 
 
 
Monocyte (Hoxa9-ER4) progenitor cells were differentiated with macrophage colony stimulating factor 
(M-CSF), which induces plasminogen receptors (▲) on these cells. Then intact cells were biotinylated 
(●) and passed over a dead cell removal column. Live cells were then lysed and membrane fractions 
prepared and passed over a plasminogen-Sepharose affinity column and specifically eluted. 
Biotinylated plasminogen receptors (▲●) were then bound to an avidin column and digested with 
trypsin. 
Fig. 3. Isolation of plasminogen receptors. 
www.intechopen.com
 Identification of the Novel Plasminogen Receptor, Plg-RKT 
 
225 
In MudPIT, the peptide mixtures were first resolved by strong cation exchange liquid 
chromatography followed by reversed phase liquid chromatography. Eluting peptides were 
electrosprayed onto an LTQ ion trap mass spectrometer and full MS spectra were recorded 
over a 400-1600 m/z range, followed by three tandem mass events. The spectra obtained 
were searched against a mouse protein database. Using this method, only one protein with a 
predicted transmembrane sequence and a C-terminal basic residue was identified: the 
hypothetical protein, C9orf46 homolog (IPI00136293), homologous to the protein predicted 
to be encoded by human chromosome 9, open reading frame 46. The peptides 
corresponding to C9orf46 homolog that were obtained in the MudPIT analysis are shown in 
Table 1. We have designated the protein, Plg-RKT, to indicate a plasminogen receptor with a 
C-terminal lysine and having a transmembrane domain (see below). [A limitation of 
shotgun proteomics, such as MudPIT, is that they typically under sample a proteome 
because they use data dependent data acquisition (a computer-driven data acquisition 
approach). This can lead to variations in the proteins identified, particularly amongst the 
lower abundant proteins. Thus, we cannot exclude the possibility that other membrane 
proteins exposing C-terminal lysines were present in the membrane proteome.] 
 
Xcorr DeltCN Conf% ObsM+H+ CalcM+H+ Peptide Sequences 
3.8378 0.2884 99.8% 2195.8743 2196.4788 K.SMNENMKNQQEFMVTHAR.L (3+) 
2.6749 0.1167 95.2% 1359.5521 1361.5181 K.NQQEFMVTHAR.L (2+) 
2.6771 0.2534 99.8% 1160.4321 1160.3514 R.HLTMQNEMR.E (2+) 
4.7468 0.3052 100% 1523.5322 1523.6954 R.MKSEAEDILETEK.T (2+) 
5.1774 0.3788 100% 2335.5544 2333.6997 R.MKSEAEDILETEKTKLELPK.G (3+) 
3.775 0.3164 100% 1264.0922 1264.3287 K.SEAEDILETEK.T (2+) 
2.995 0.0655 96.8% 1137.2722 1137.3184 K.GLITFESLEK.A (2+) 
2.893 0.2591 99.7% 1364.4922 1364.5848 K.GLITFESLEKAR.R (2+) 
SEQUEST-defined parameters (Xcorr, DeltCN, and Conf%) are shown for each peptide. (core: cross-
correlation score; DeltCN: normalized difference in cross-correlation scores; Conf%: confidence level of 
the peptide; ObsM+H+: observed peptide mass; CalcM+H+: theoretical peptide mass). Observed 
peptide mass, theoretical peptide mass, and charges of the peptide identified (3+ or 2+) are also shown 
to demonstrate accurate peptide identification. This research was originally published in Blood, 
Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, J.R., III, 
Parmer, R.J., Miles, L.A., Proteomics-based discovery of a novel, structurally unique, and 
developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface 
plasminogen activation, Blood. 2010, 115: 1319-30. 
Table 1. Peptides obtained corresponding to C9orf46 homolog  
A key advantage of MudPIT is that proteins in a given proteome can be identified 
simultaneously. As proof of principle of our isolation method, peptides corresponding to 
other proteins previously identified as plasminogen binding proteins on monocytes were 
also detected in the membrane preparations: ǂ-enolase, gamma actin, S100A10, histone H2B, 
annexin 2, and ǃ2 integrin. 
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Table 2. Alignment of Orthologs of Plg-RKT 
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3.2 Conservation of Plg-RKT across species 
The C9orf46 homolog/Plg-RKT murine DNA sequence encodes a protein of 147 amino acids 
with a molecular mass of 17,261 Da and a C-terminal lysine (Table 2, first line). We blasted 
the C9orf46 homolog/Plg-RKT sequence against all species using NCBI Blast and obtained 
unique human, rat, dog, cow, dog, giant panda, gibbon, horse, pig, rabbit, and rhesus 
monkey predicted orthologs, with high identity and homology (e.g. human versus rhesus 
monkey = 99% similarity), high identity (e.g. human vs rhesus monkey = 98% identity) and 
no gaps in the sequence (Table 2). Of key importance, a C-terminal lysine was predicted for 
all of the mammalian orthologs obtained in the blast search. In a query of the Ensembl Gene 
Report, DNA sequences of all 10 other sequenced mammalian orthologs encoded C-terminal 
lysines (Table 2).  
In addition, the DNA sequences of xenopus and the green lizard also encoded C-terminal 
lysines (Table 2). Furthermore, Plg-RKT orthologs with 149 amino acids with a C-terminal 
lysine were encoded in bony fish (salmon and zebrafish) and the high similarity with a 
mammalian ortholog is illustrated in the alignment of the mouse and zebrafish proteins in 
Table 3.  
The Plg-RKT sequence also encodes a putative conserved DUF2368 domain (encompassing 
amino acids 1-135), an uncharacterized protein with unknown function conserved from 
nematodes to humans. Notably, Plg-RKT orthologs of lower organisms were of different 
predicted lengths and did not consistently predict C-terminal lysines. It is interesting to note 
that the evolutionary origin of plasminogen is currently believed to originate with 
protochordates (Liu & Zhang, 2009), so that lower organisms without plasminogen would 
not utilize the C-terminal lysine of Plg-RKT to bind plasminogen. 
 
 
Table 3. Alignment of Mouse and Zebrafish Plg-RKT Sequences 
It is also noteworthy that the primary sequence of C9orf46 homolog/Plg-RKT is apparently 
tightly conserved in humans, with no validated polymorphisms (cSNPs) within the 6 exons 
encoded by the gene (on chromosome 9p24.1) in the NCBI human genome sequence 
variation database (dbSNP, http://www.ncbi.nlm.nih.gov/SNP). 
3.3 Topology of Plg-RKT 
The C9orf46 homolog/Plg-RKT sequence was analyzed in the TMpred site 
(www.ch.embnet.org/cgi-bin/TMPRED). The model predicted two transmembrane helices 
extending from F53-L73 (secondary helix, oriented from outside the cell to inside the cell) and 
P78-Y99 (primary helix, oriented from inside the cell to outside the cell) (Figure 4). Hence a 52 
amino acid N-terminal region and a 48 amino acid C-terminal tail with a C-terminal lysine 
were predicted to be exposed on the cell surface. 
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Green indicates amino acids within the predicted primary transmembrane helix. Orange indicates 
amino acids within the predicted secondary transmembrane helix. Red indicates basic amino acids. This 
research was originally published in Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., 
Kiosses, W.B., Kamps, M.P., Yates, J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based discovery of a 
novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major 
regulator of cell surface plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 4. Structural model of Plg-RKT. 
We experimentally tested predictions of the model. First, we raised a monoclonal antibody 
against the synthetic peptide, CEQSKLFSDK (corresponding to the nine C-terminal amino 
acids of murine Plg-RKT with an amino terminal cysteine added for coupling). To examine 
subcellular localization, membrane and cytoplasmic fractions from progenitor and 
differentiated Hoxa9-ER4 monocyte progenitor cells were electrophoresed and western 
blotted with anti-Plg-RKT mAb or isotype control mAb. A specific immunoreactive band 
migrating with an Mrapp of ~17,000, was detected in membrane fractions of differentiated 
monocyte progenitor cells, clearly demonstrating the existence of this new protein (Figure 
5,A). The protein was not detected in undifferentiated cells or in the cytoplasmic fraction of 
the differentiated cells. 
To test the prediction that Plg-RKT is an integral membrane protein, membranes from 
differentiated monocyte progenitor cells were subjected to phase separation in Triton X-114 
as described (Bordier, 1981; Estreicher et al., 1989). In this method, integral membrane 
proteins form mixed micelles with the nonionic detergent and are recovered in the Triton X-
114 detergent phase, whereas hydrophilic proteins remain in the aqueous phase. An 
immunoreactive band migrating with an Mrapp of ~17,000 was detected in the detergent 
phase in western blotting with anti-Plg-RKT mAb, but was not detected in the aqueous phase 
(Figure. 5,B). These data support the prediction that Plg-RKT is an integral membrane 
protein. 
To experimentally test whether the C-terminal lysine of Plg-RKT was exposed on the cell 
surface, we treated intact biotinylated cells with carboxypeptidase B prior to performing our 
isolation procedure. Under this condition, C-terminal lysines exposed on the cell surface are  
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A. Membrane fractions or cytoplasmic fractions from either undifferentiated or M-CSF-treated Hoxa9-
ER4 cells were electrophoresed on 12% sodium dodecyl sulfate polyacrylamide gels under reducing 
conditions and western blotted with either anti-Plg-RKT mAb, anti-ǂ-enolase mAb as a loading control, 
or isotype control mAb. B. M-CSF-treated Hoxa9-ER4 cell membranes were solubilized in 3% Triton X-
114. After heating at 37ºC and separation of the phases by centrifugation, an aliquot of both phases was 
electrophoresed and western blotted with anti-Plg-RKT mAb. This research was originally published in 
Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, 
J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based discovery of a novel, structurally unique, and 
developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface 
plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 5. Plg-RKT behaves as a regulated integral membrane protein. 
removed but intracellular C-terminal lysines are protected (see Figure 2,B). Under this 
condition, no peptides corresponding to Plg-RKT were obtained in the MudPIT analysis, 
consistent with cell surface exposure of the C-terminal lysine of Plg-RKT.  
In order to experimentally evaluate whether the N-terminus of Plg-RKT was exposed on the 
cell surface, PC12 (rat pheochromocytoma) cells were stably transfected with V5-pCIneo-
Plg-RKT that expressed a V5 tag at the N-terminus of Plg-RKT. (The V5 sequence was added 
in front of the mammalian expression vector, pCIneo using PCR and then the full-length 443 
bp Plg-RKT cDNA was subcloned into the V5-pCIneo vector using the Xho1 and Sma1 
cloning sites. Constructs were transfected into cells using Lipofectamine 2000 and  stable 
transfectants were selected with G418.) 
A specific band migrating with a Mrapp of 17,000 was detected in cell membranes of the 
stably transfected cells with both anti-V5 mAb and anti-Plg-RKT mAb (Figure 6, lane 1). The 
band was not detected by either mAb after trypsin digestion of the isolated membrane 
fraction (lane 2). When intact cells were incubated with trypsin and the trypsin neutralized  
with SBTI prior to preparation of the membrane fraction, the majority of the band detectable 
with either anti-V5 or anti-Plg-RKT was lost (lane 4). In controls, treatment with soybean 
trypsin inhibitor (SBTI) fully neutralized the ability of trypsin to degrade the V5-tagged Plg-
RKT in purified membrane fractions (lane 3), demonstrating that the trypsin had been 
neutralized prior to membrane fractionation of the treated cells. These results suggest that 
the N- terminus of Plg-RKT is accessible to trypsin proteolysis of intact cells and is, therefore,  
www.intechopen.com
 Proteomics – Human Diseases and Protein Functions 
 
230 
 
Membrane fractions of PC12 cells stably transfected with V5-pCIneo-Plg-RKT were incubated with either 
buffer (lane 1), trypsin (1mg/ml ) (lane 2) or trypsin 1 mg/ml  + soybean trypsin inhibitor (SBTI) (2 
mg/ml) (lane 3) for 30 minutes at 37ºC or intact PC12 cells were incubated with 1 mg/ml trypsin for 2 
hr at 37ºC, followed by 2 mg/ml SBTI for 15 min . Following neutralization of trypsin with SBTI, the 
membrane fraction was prepared from the treated, intact cells (lane 4). 30 µg/lane of membrane 
fractions were electrophoresed on 18% SDS PAGE under reducing conditions and western blotted with 
either anti-V5, anti-Plg-RKT mAb  or isotype control. 
Fig. 6. The N-termini and C-termini of Plg-RKT are exposed on the cell surface. 
exposed on the extracellular face. Furthermore, because the anti-Plg-RKT mAb reacts with 
the C-terminus of Plg-RKT, these data also confirm the exposure of the C-terminus on the 
extracellular face of the cell membrane. 
3.4 Role of the C-terminal lysine of Plg-RKT in plasminogen binding 
We further addressed the exposure of the C-terminus of Plg-RKT on the cell surface using 
confocal microscopy with a mAb raised against the Plg-RKT C-terminal peptide. (The mAb 
reacted with the C-terminal peptide of murine Plg-RKT and blocked plasminogen binding to 
CEQSKLFSDK). When cells were incubated with  anti-Plg-RKT mAb and a polyclonal anti-
plasminogen antibody, Plg-RKT and plasminogen were both immunodetected in small 
aggregates dispersed over the cell surface (Figure 7,A), in a similar distribution to that 
published for confocal analyses of monocyte-associated plasminogen (Das et al., 2007). Most 
importantly, after preincubation of monocytes with plasminogen, immunodetection of Plg-
RKT was reduced by half (Figure 7,A,B). These results demonstrate that the C-terminus of 
Plg-RKT is exposed on the cell surface. Furthermore, these results show that plasminogen 
binds to the C-terminal domain of Plg-RKT on the cell surface. 
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A. M-CSF-differentiated (Hoxa9-ER4) cells were grown on coverslips  and preincubated with either 
phosphate buffered saline (- plasminogen) or 2 μM plasminogen (+ plasminogen), then fixed in 1% 
formaldehyde, washed and stained with polyclonal anti-plasminogen IgG or anti-Plg-RKT mAb and 
stained with a combination of Alexa 488- F(ab’)2  of goat anti-rabbit IgG and Alexa 568- F(ab’)2 fragment 
of goat anti-mouse IgG. 
B. The number and size of each labeled aggregate was determined. The results reflect counts from over 
40 cells in 2 independent experiments. Data represent mean ± SEM. *p < 0.001. This research was 
originally published in Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., Kiosses, 
W.B., Kamps, M.P., Yates, J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based discovery of a novel, 
structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of 
cell surface plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 7. Plg-RKT binds plasminogen on the cell surface. 
To further address the plasminogen binding function of the C-terminus of Plg-RKT , we 
tested whether the synthetic peptide, corresponding to the C-terminus of Plg-RKT could bind 
plasminogen. The peptide, CEQSKLFSDK, was coupled to BSA and then coated onto wells 
of microtiter plates. Biotinylated Glu-plasminogen was incubated with the wells and specific 
binding was detected with HRP-streptavidin (Figure 8). We tested the ability of the soluble 
C-terminal peptide to inhibit Glu-plasminogen binding under solution phase equilibrium 
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conditions. The soluble peptide competed for Glu-plasminogen binding in a dose-
dependent manner with an IC50 of 2 μM (Figure 8), similar to the Kd values we have 
previously determined for Glu-plasminogen binding to cells (Miles et al., 2005). In addition, 
a mutated peptide with the C-terminal lysine substituted with alanine did not compete for 
plasminogen binding at concentrations up to 1 mM (Figure 8), further supporting the role of 
the C-terminal lysine in the interaction of Plg-RKT with plasminogen.  
 
 
The peptide, CEQSKLFSDK, was coupled to BSA and immobilized on microtiter wells. Biotinylated-Glu-
plasminogen (25 nM) was incubated with immobilized CEQSKLFSDK in the  presence of increasing 
concentrations of CEQSKLFSDK (●) or a K147A mutant peptide, CEQSKLFSDA (○). Biotinylated Glu-
plasminogen binding was detected with HRP-streptavidin. Data are as mean ± SEM, n=3, for each 
determination. This research was originally published in Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, 
H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based 
discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a 
major regulator of cell surface plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 8. Plasminogen binds to the C-terminal peptide of Plg-RKT. 
3.5 Plg-RKT regulates cell surface plasminogen activation 
We verified that plasminogen activation was promoted in the presence of differentiated 
Hoxa9-ER4 cells. Plasminogen activation was stimulated 12.7-fold in the presence of 
differentiated monocyte progenitor cells, compared to the reaction in the absence of cells 
(Figure 9). In order to test the role of Plg-RKT in plasminogen activation, we tested the effect 
of anti-Plg-RKT mAb raised against the synthetic peptide, CEQSKLFSDK . Anti-Plg-RKT mAb 
substantially suppressed cell-dependent plasminogen activation (Figure 9). In controls, 
plasminogen activation in the absence of cells was not affected by anti-Plg-RKT mAb. 
3.6 Tissue and cellular distribution and regulation of the Plg-RKT transcript 
We searched results of gene expression array analyses for expression of the C9orf46 
homolog/Plg-RKT transcript. The transcript is broadly expressed in normal human and 
mouse tissues [as determined in high-throughput gene expression profiling in which RNA 
samples from human and murine tissues were hybridized to high-density gene expression 
arrays (Su et al., 2002; Su et al., 2004)]. The C9orf46 homolog/Plg-RKT transcript has been  
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Plasminogen activation was determined in either the presence or absence of differentiated Hoxa9-ER4 
cells and in the presence of either anti-Plg-RKT mAb (filled bars) or isotype control rat IgG2a (open bars). 
***p < 0.001, compared to the corresponding isotype control. This research was originally published in 
Blood, Andronicos, N.M., Chen, E.I., Baik, N., Bai, H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, 
J.R., III, Parmer, R.J., Miles, L.A., Proteomics-based discovery of a novel, structurally unique, and 
developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface 
plasminogen activation, Blood. 2010, 115: 1319-30. 
Fig. 9. Plg-RKT regulates cell surface plasminogen activation. 
detected in spleen, lymph node, thymus, bone marrow, lung, intestine, adrenal, pituitary, 
and other endocrine tissues, vascular tissue, kidney, liver, stomach, bladder, and neuronal 
tissue (hippocampus, hypothalamus, cerebellum, cerebral cortex, olfactory bulb and dorsal 
root ganglion) (Table 4). 
We also searched for C9orf46 homolog/Plg-RKT mRNA microarray expression data at 
http://www.ebi.ac.uk/microarray-as/aew/. C9orf46 homolog/Plg-RKT mRNA is present in 
monocytes, leukocytes, natural killer (NK) cells, T cells, myeloid, dendritic, and 
plasmacytoid cells, breast cancer, acute lymphoblastic leukemia and Molt-4 acute 
lymphoblastic leukemia cells (Table 5).  
 
 Spleen  Liver 
 Thymus  Stomach 
 Lymph Node  Bladder 
 Lung  Hippocampus 
 Intestine  Hypothalamus 
 Bone Marrow  Cerebellum 
 Adrenal  Cerebral Cortex 
 Pituitary  Olfactory Bulb 
 Vascular Tissue  Dorsal Root Ganglion 
 Kidney  
Results of high-throughput gene expression profiling (54). 
Table 4. Tissue Distribution of Plg-RKT mRNA 
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 Monocytes  B-cell precursor cells 
 NK cells  Acute lymphoblastic leukemia cells 
 T cells  Molt-4 acute lymphoblastic leukemia cells 
 Myeloid cells  Breast cancer cells, SKBR3, MDA468, BT474, T47D 
 Dendritic cells  
 Plasmacytoid cells  
www.ebi.ae.uk/microarray-as/aew/ 
Table 5. Microarray Expression Data for Plg-RKT mRNA 
These data are consistent with previous reports documenting expression of plasminogen 
binding sites on peripheral blood leukocytes (Miles & Plow, 1987), breast cancer cells 
(Correc et al., 1990; Ranson et al., 1998) and other tissues [reviewed in (Miles et al.,  
2005)]. In addition, results obtained by searching the ArrayExpress Warehouse 
(http://www.ebi.ac.uk/microarray) indicated that the C9orf46 homolog gene is also 
regulated in other tissues by lipopolysaccharide, aldosterone, canrenoate, H2O2, and 
dexamethasone (Table 6). 
In a previously published genome-scale quantitative image analysis, overexpression of a 
cDNA that we now recognize to be the Plg-RKT cDNA, resulted in dramatic increases in cell 
proliferation whereas knockdown of the corresponding mRNA resulted in apoptosis 
(Harada et al., 2005). Consistent with an anti-apoptotic role of Plg-RKT, we have shown that 
cell-bound plasminogen inhibits TNFǂ-induced apoptosis (Mitchell et al., 2006). In 
microarray studies, C9orf46 homolog mRNA expression has a high power to predict cervical 
lymph node metastasis in oral squamous cell carcinoma (Nguyen et al., 2007).  
 
Experiment Tissue Agonist Effect* 
E-MEXP-420 Hippocampal microglial cells lipopolysaccharide ↓ 
E-TABM-229 Kidney aldosterone ↓ 
E-TABM-229 Kidney canrenoate ↓ 
E-MEXP-710 Cholinergic cells H2O2 ↓ 
E-MEXP-774 Preadipocytes Dexamethasone ↓ 
Data were obtained from ArrayExpress Warehouse (http://www.ebi.ac.uk/microarray). 
* ↓ = downregulation. This research was originally published in Blood, Andronicos, N.M., Chen, E.I., 
Baik, N., Bai, H., Parmer, C.M., Kiosses, W.B., Kamps, M.P., Yates, J.R., III, Parmer, R.J., Miles, L.A., 
Proteomics-based discovery of a novel, structurally unique, and developmentally regulated 
plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation, Blood. 2010, 
115: 1319-30. 
Table 6. Regulation of C9orf46 homolog/Plg-RKT mRNA in Tissues 
4. Conclusions 
In conclusion, MudPIT has allowed us to identify a new protein, Plg-RKT, a novel 
plasminogen receptor with unique characteristics: integral to the cell membrane and 
exposing a C-terminal lysine on the cell surface in an orientation to bind plasminogen and 
promote plasminogen activation. Thus, Plg-RKT is likely to play a key role in plasminogen-
dependent functions of cells including inflammation, wound healing, development, 
metastasis, neurite outgrowth, fibrinolysis, myogenesis and prohormone processing. The 
www.intechopen.com
 Identification of the Novel Plasminogen Receptor, Plg-RKT 
 
235 
broad distribution of the Plg-RKT transcript and its regulation in tissues that have been 
demonstrated to express plasminogen binding sites, suggest that Plg-RKT provides 
plasminogen receptor function that may serve to modulate plasmin proteolytic functions 
(both physiologic and pathologic) specific to a large number of tissues. Furthermore, the 
potential function of Plg-RKT in the regulation of apoptosis and proliferation may play a key 
role in cancer and metastasis. Future studies with knockout mice should build on our initial 
results using MudPIT to elucidate the role of Plg-RKT. 
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Proteomic Discovery of Disease Biomarkers, Proteomic Analysis of Protein Functions, Proteomic Approaches
to Dissecting Disease Processes, and Organelles and Secretome Proteomics. We believe that clinicians,
students and laboratory researchers who are interested in Proteomics and its applications in the biomedical
field will find this book useful and enlightening. The use of proteomic methods in studying proteins in various
human diseases has become an essential part of biomedical research.
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